Query: NC_005296:5238882 Rhodopseudomonas palustris CGA009, complete genome Lineage: Rhodopseudomonas palustris; Rhodopseudomonas; Bradyrhizobiaceae; Rhizobiales; Proteobacteria; Bacteria General Information: Environmental bacterium with potential use in bioremediation. This organism has a diverse metabolism and is capable of growth using light, inorganic, or organic compounds as energy sources and carbon dioxide or organic compounds as carbon sources. Commonly found in soil and water environments this bacterium is also capable of degrading a wide range of toxic organic compounds, and may be of use in bioremediation of polluted sites. The bacterium undergoes differentiation to produce a stalked nonmotile cell and a motile flagellated cell. In the presence of light, this bacterium produces a number of intracellular membranous vesicles to house the photosynthetic reaction centers.
- Sequence; - BLASTN hit (Low score = Light, High score = Dark) - hypothetical protein; - cds: hover for description
General Information: This organism was first isolated from the soil in Vineland, New Jersey, although it is found worldwide. It is a large obligate aerobe that has one of the highest respiratory rates of any organism. Azotobacter vinelandii also produces a number of unusual nitrogenases which allow it to fix atmospheric nitrogen to ammonia, a compound it can then use as a nitrogen source. It protects the oxygen-sensitive nitrogenase enzymes through its high respiratory rate, which sequesters the nitrogenase complexes in an anoxic environment. This organism has a number of unusual characteristics. Under extreme environmental conditions, the cell will produce a cyst that is resistant to dessication and is surrounded by two capsular polysaccharide layers. This organism produces two industrially important polysaccharides, poly-beta-hydroxybutyrate (PHB) and alginate. PHB is a thermoplastic biopolymer, and alginate is used in the food industry. Alginate is also used by the pathogen Pseudomonas aeruginosa to infect the lungs of cystic fibrosis patients.